Ceftriaxone in Patients with ALS
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To determine the pharmacokinetics, safety and tolerability of
long term cefriaxone treatment as well as to ascertain whether chronic
treatment with ceftriaxone prolongs survival in patients with ALS.
Who is Eligible to Participate?
Patients 18 years or older with familial or sporadic ALS. Patients
will also have to meet all exclusionary criteria which will be explained
in greater detail by the study coordinator.
What is involved in this Study?
Patients 18 years or older with familial or sporadic ALS. Patients
may be on riluzole, but have to be on a stable dose for at least 30 days
prior to screening. Patients will also have to meet all exclusionary
criteria which will be explained in greater detail by the study coordinator.
How long is the Study?
The study will be approximately 52 weeks long.
For More Information Contact: Nicole C. Hank, MHSM, study coordinator,
at 602-258-3354 ext 137 or nhank@pnal.net or
call the Main line at 602-258-3354
